Congresses and Events
![](https://www.bostonscientific.com/en-EU/medical-specialties/interventional-cardiology/intouch-newsletter/intouch-newsletter-q1-2017/congresses-and-events/_jcr_content/maincontent-par/image.img.intouch_nl_banner_en_1_645x175px_eu.jpg)
Three-year Results from the EVOLVE II Randomized Trial presented at ACC
![EVOLVE II clinical trial, outstanding Safety and Performance](https://www.bostonscientific.com/en-EU/medical-specialties/interventional-cardiology/intouch-newsletter/intouch-newsletter-q1-2017/congresses-and-events/_jcr_content/maincontent-par/image_0.img.intouch_newsletter_issue_4_topic_1_1_960x480px_eu.jpg)
Three-year follow-up from EVOLVE II trial presented by Dr. Dean Kereiakes supports longer-term safety and efficacy of the novel abluminal bioabsorbable polymer SYNERGY™ everolimus-eluting stent in a broad range of patients undergoing PCI.
Synergy™ BP Stent Launches 48mm Length
![Heal long lesions with confidence](https://www.bostonscientific.com/en-EU/medical-specialties/interventional-cardiology/intouch-newsletter/intouch-newsletter-q1-2017/congresses-and-events/_jcr_content/maincontent-par/image_1.img.intouch_newsletter_issue_4_topic_1_2_960x480px_eu.jpg)
Long lesions represent a complex lesion subset that is associated with increased safety related events, reduced efficacy and increased procedure time. SYNERGY™ BP Stent was designed for quality healing and safety over time and with the addition of a 48mm length it has a complete size matrix to address these complex lesions.
Boston Scientific announces Agreement to acquire Symetis
![ACURATE TA™](https://www.bostonscientific.com/en-EU/medical-specialties/interventional-cardiology/intouch-newsletter/intouch-newsletter-q1-2017/congresses-and-events/_jcr_content/maincontent-par/image_2.img.intouch_newsletter_issue_4_topic_1_3_960x480px_eu.jpg)
Boston Scientific announced a definitive agreement to acquire Symetis SA. The Symetis portfolio includes the ACURATE TA™ and ACURATE neo/TF valve* systems for use in the treatment of high-risk patients suffering from severe and symptomatic aortic valve stenosis.